Alvotech issues 12.5 million shares to subsidiary for $65 million
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Alvotech Announces Increase in Number of Own Shares
February 11, 2026 11:00 AM ESTREYKJAVIK, ICELAND (February 11, 2026) Alvotech (NASDAQ: ALVO) (the Company), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share capital by an amount of one hundred and twenty-five thousand (USD 125,000) by issuing twelve million and five-hundred thousand (12,500,000) ordinary shares. The Companys subsidiary, Alvotech Manco ehf. (the subsidiary), has subscribed to all of the newly issued shares for a price of USD 5.2 per share. The shares held by the subsidiary are treated as treasury shares without voting rights or dividend entitlement.
Following the above-mentioned... More
